Analyst
Berenberg
Equibles does not estimate personal net worth.
Harry Gillis is recorded as Analyst at Berenberg. Harry Gillis has spoken on 4 earnings calls across 3 companies, most recently for Sartorius AG on October 22, 2026. Those appearances were for Qiagen N.V. (QGEN), Sartorius AG (SOAGY) and Sartorius Stedim Biotech S.A. (SDMHF). The companies whose calls Harry Gillis spoke on are classified in the Healthcare sector.
“I want to push a little bit more on what the strength from AI drug-driven drug discovery workflows means in practice. Is this sort of AI-native companies? Is it biotech, potentially benefiting from biotech funding, or is it large pharma companies in terms of the customer category?”
“Your underlying BPS growth accelerated to 8.4% in Q2 from 8.1% in Q1, despite the delays at the two advanced modality customers. All your commentary indicates that markets are improving. you still expect equipment growth in H2.”
“Just following up on the previous questions relating to the step up in your margin through the rest of the year, I was just wondering if you could maybe discuss whether the Middle least conflict is having any impact on your raw material freight or energy costs and what's your exposure there should the conflict persist…”
“There were headlines a few weeks ago around Kyogen as a potential deal target. Again, I was wondering what comments, if any, you can share on that.”
Berenberg
Analyst
Transcript header (unverified)
QGEN
Diagnostics & Research · Healthcare
SOAGY
Medical Instruments & Supplies · Healthcare
Medical Instruments & Supplies · Healthcare
